Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable single-dose vials of the ...

Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.16% and ...

Recent studies and clinical trials have been finding that these drugs also have health benefits beyond weight loss. Popular ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Spotting Ozempic and GLP-1-friendly meals in the frozen food aisle at your local grocery store just got easier.

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Jeffrey Segal MD, JD, a medico-legal expert and the founder of Medical Justice, discussed the shifting dynamics of the market for GLP-1 receptor agonist medications in a recent blog, “The Whirlwind ...

Robert F. Kennedy Jr., a prominent critic of the pharmaceutical industry, discussed his views regarding GLP-1 weight loss drugs in a televised broadcast.

Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and ...